tbuckley/cabot-search huggingface dataset:
Postmenopausal hormone therapy and risk of venous thromboembolism: what about progesterone?
Authors: Pierre-Yves Scarabin
Journal: BMJ (2019)

The UK study by Vinogradova and colleagues provides further evidence that oral but not transdermal oestrogen is associated with increased risk of venous thromboembolism among women who use postmenopausal hormone therapy.1 Previous studies have shown this safety advantage of transdermal oestrogen, together with the important role of concomitant progestogens.23

Progesterone is …
miRs-206-3p and -381-3p Regulated Calcineurin-NFAT Signaling Upregulates Induced Nitric Oxide Synthase (iNOS) Transcription After 4,4’-Methylene Diphenyl Diisocyanate Exposure
Authors: Chen-Chung Lin, Brandon F. Law, Paul D. Siegel, Justin M. Hettick
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 12525: The Long-term Need for Repeat Coronary Revascularization after Coronary Artery Bypass Surgery: the Society of Thoracic Surgeons' National Experience, 1990-2007
Authors: Emil L Fosbol, Yue Zhao, David M Shahian, Frederick L Grover, Fred H Edwards, Eric D Peterson
Journal: Circulation (2012)

Background: An advantage of coronary artery bypass graft surgery (CABG) relative to percutaneous coronary intervention (PCI) is its durability, yet there is a paucity of information on the long-term need for and predictors of repeat coronary revascularization following CABG in the modern era. Methods: We included patients 65 years and older undergoing first-time isolated CABG from 1991 to 2007 (n=723,134, median age 73 years) included in the Society of Thoracic Surgeons (STS) National Adult Cardiac Surgery Database linked to Medicare claims data. Long-term outcomes (up to 18 years following CABG) were examined using cumulative incidence and Kaplan-Meier curves. Multivariable Cox proportional hazard analysis was used to identify factors associated with 1-year and 5-year repeat revascularization trends and their variability among United States centers. Results: By 18 years following CABG, the overall survival rate was 20% in this older cohort. Cumulative incidences of any repeat revascularization (PCI or CA...
A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA).
Authors: Megan Greally, Sujata Jha, Sam S. Yoon, Jia Li, Avni Mukund Desai, Elizabeth Won, David Paul Kelsen, David H. Ilson, Yelena Yuriy Janjigian, Kathrena Aljallad, Geoffrey Yuyat Ku
Journal: Journal of Clinical Oncology (2019)

116 Background: PTX/RAM as 2L tx for patients (pts) with EGA is a standard-of-care based on the RAINBOW trial (Lancet Oncol 2014;15:1224). However, benefit is modest. Upregulation of the platelet-derived growth factor (PDGF)/PDGF receptor-β (PDGFR-β) pathway causes resistance to VEGF inhibition. Crenolanib is a selective inhibitor of PDGFR-β. We report initial results of the dose escalation phase of a study of crenolanib plus RAM/PTX in pts with previously treated advanced EGA. Methods: This phase I/Ib study is enrolling ECOG PS 0-1 EGA pts with progression on first-line chemo. PTX 80 mg/m 2 / day on day 1, 8, 15 and RAM 8mg/kg q 14 days were administered with escalating doses of crenolanib (60, 80, 100 mg BID) after a 7 day “run-in” of crenolanib to assess crenolanib-related toxicities. The primary objective was to determine the maximum tolerated dose (MTD) of crenolanib plus RAM/PTX. Safety and preliminary efficacy were examined. Results: 15 pts were treated; 12 male, median age 58 (32-73), 66% were ECOG PS 1. Primary site was gastric in nine pts, GEJ in 4 pts and esophageal in two pts. Three pts each received crenolanib 60mg BID and 80mg BID, six pts received 100mg BID and three pts received higher doses. At data cutoff, eight pts continued on treatment. 12 pts have completed the DLT evaluation period across 3 dose levels (60 to 100 mg BID). Median treatment duration was 76 days (35-191). The combination was well tolerated, with no DLTs or serious adverse events (SAEs) attributed to study drug. Treatment related adverse events occurred in two pts (17%), all grade 1. These were fatigue, nausea, vomiting and hypertension. Disease progression was the most common reason for treatment discontinuation; no pt discontinued due to study drug related AEs. Nine pts were evaluable for response. One pt had objective response; the disease control rate was 78%. Median PFS and OS were 4.1 and 11.9 months respectively. Conclusions: Crenolanib plus RAM/PTX appears well tolerated at a dose level of 100mg BID. Further evaluation is needed to determine efficacy. Accrual is ongoing at higher doses. Once the MTD is defined, the dose expansion phase will enroll 25 pts. Updated data with pharmacokinetics and biomarkers will be presented. Clinical trial information: NCT03193918.
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus
Authors: Dimitrios Rigopoulos, Robert Baran, Soumiya Chiheb, Carlton Ralph Daniel, Nilton Di Chiacchio, Stamatis Gregoriou, Chander Grover, Eckart Haneke, Matilde Iorizzo, Marcel Pasch, Bianca Maria Piraccini, Phoebe Rich, Bertrand Richert, Natalia Rompoti, Adam I. Rubin, Archana Singal, Michela Starace, Antonella Tosti, Ioanna Triantafyllopoulou, Martin Zaiac
Journal: Journal of the American Academy of Dermatology (2019)
Abstract 11184: Factors Associated With Lack of Reperfusion Therapy Among Oldest-Old Patients With Acute Myocardial Infarction: A Nationwide Retrospective Cohort Study in Japan
Authors: Toshiaki Isogai, Hiroki Matsui, Hiroyuki Tanaka, Kiyohide Fushimi, Hideo Yasunaga
Journal: Circulation (2018)

Introduction: Previous studies reported that elderly patients with acute myocardial infarction (AMI) were less likely to receive reperfusion therapy than younger patients. However, it remains uncle...
Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial
Authors: Emanuele Pivetta, Alberto Goffi, Peiman Nazerian, Davide Castagno, Camilla Tozzetti, Pietro Tizzani, Maria Tizzani, Giulio Porrino, Enrico Ferreri, Valeria Busso, Fulvio Morello, Cristina Paglieri, Monica Masoero, Elisa Cassine, Federica Bovaro, Stefano Grifoni, Milena M. Maule, Enrico Lupia
Journal: European Journal of Heart Failure (2019)
Healing Pulmonary Rehabilitation in the United States. A Call to Action for ATS Members
Authors: Chris Garvey, Richard S. Novitch, Phillip Porte, Richard Casaburi
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

wall morphology and function at 7 days in some preterm infants is indicative of elevated pressures seen in PH (2,14).Emerging, noninvasive indices of PVD (e.g., RV systolic time intervals [7], measures of RV function [e.g., strain parameters (14)]) that more broadly capture components of RV performances and afterload (pressure, resistance, and compliance) may prove to be more informative than pressure estimates alone.Early evidence of PVD in preterm infants adds to the growing list of complications of being born premature that may increase susceptibility or be a marker for greater risk of late pulmonary disease beyond the neonatal period and into early childhood, adolescence, and adulthood (8,15).Adding these results to their previous work, Mourani and colleagues have now shown that echocardiographic evidence of PVD at 1 week of age is an early predictor of BPD, late PH, and late respiratory disease (11).Newborns with PVD may be particularly susceptible to secondary insults; future studies should use these early risk factors as predictive biomarkers toward enrolling the highest-risk infants into clinical intervention trials (6).
Johnson and Johnson pays $120m to settle hip implant claims from 46 US states
Authors: Owen Dyer
Journal: BMJ (2019)

Johnson and Johnson, and its subsidiary DePuy Orthopaedics, have agreed to pay $120m (£92m; €106m) to settle claims from a coalition of attorneys-general from 46 US states that they endangered consumers by falsely advertising and misrepresenting the durability of their hip implantation devices.

The settlement ends the legal battle over metal hip implants for the states, but not for the manufacturer, which still faces over 10 thousand individual claims. These claims relate to two …
Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
Authors: Arye Rubinstein, Tracy A. Bridges, H. James Wedner, Donald McNeil, Richard L. Wasserman, Raffi Tachdjian, Steven V. Stryk, Martha M. Tarpay, Katharina Fielhauer, Heinz Leibl, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2019)
Antigen-presenting ILC3 regulate T cell–dependent IgA responses to colonic mucosal bacteria
Authors: Felipe Melo-Gonzalez, Hana Kammoun, Elza Evren, Emma E. Dutton, Markella Papadopoulou, Barry M. Bradford, Ceylan Tanes, Fahmina Fardus-Reid, Jonathan R. Swann, Kyle Bittinger, Neil A. Mabbott, Bruce A. Vallance, Tim Willinger, David R. Withers, Matthew R. Hepworth
Journal: The Journal of Experimental Medicine (2019)

Intestinal immune homeostasis is dependent upon tightly regulated and dynamic host interactions with the commensal microbiota. Immunoglobulin A (IgA) produced by mucosal B cells dictates the composition of commensal bacteria residing within the intestine. While emerging evidence suggests the majority of IgA is produced innately and may be polyreactive, mucosal-dwelling species can also elicit IgA via T cell–dependent mechanisms. However, the mechanisms that modulate the magnitude and quality of T cell–dependent IgA responses remain incompletely understood. Here we demonstrate that group 3 innate lymphoid cells (ILC3) regulate steady state interactions between T follicular helper cells (TfH) and B cells to limit mucosal IgA responses. ILC3 used conserved migratory cues to establish residence within the interfollicular regions of the intestinal draining lymph nodes, where they act to limit TfH responses and B cell class switching through antigen presentation. The absence of ILC3-intrinsic antigen presentation resulted in increased and selective IgA coating of bacteria residing within the colonic mucosa. Together these findings implicate lymph node resident, antigen-presenting ILC3 as a critical regulatory checkpoint in the generation of T cell–dependent colonic IgA and suggest ILC3 act to maintain tissue homeostasis and mutualism with the mucosal-dwelling commensal microbiota.
Egg Oral Immunotherapy (OIT) Induces More Rapid Desensitization and Sustained Unresponsiveness (SU) in Egg-Allergic, Baked-egg Tolerant Children than the Addition of Daily Baked-egg Products
Authors: Hugh A. Sampson, Donald Y.M. Leung, Stacie M. Jones, Scott H. Sicherer, A. Wesley Burks, Alice Henning, Robert W. Lindblad, Peter Dawson, Tamara T. Perry, Edwin Kim, Robert A. Wood
Journal: Journal of Allergy and Clinical Immunology (2019)
Survival outcomes of left-sided versus right-sided colon cancer.
Authors: Jasmine Lizette Gowarty, Charis Durham, Lucas Wong, Wencong Chen
Journal: Journal of Clinical Oncology (2019)

502 Background: Right-sided colon cancers (RCC) are defined up to the splenic flexure where as left-sided colon cancers (LCC) involve the descending, sigmoid, and rectosigmoid regions. The landmark CALGB/SWOG 80405 study concluded that sidedness was an independent prognostic factor for survival in stage IV adenocarcinoma of the colon or rectum, with a poorer prognosis in RCC. This raises the question as to whether or not stage of malignancy plays a role. We performed a retrospective analysis on survival for stage I to IV colon cancer treated at our institution in order to assess if tumor location is an independent prognostic factor as described in previous studies. Methods: Primary site of cancer, sex, age at diagnosis, vital status, and year of diagnosis for stage I, II, III, and IV colon cancer was collected from our institution’s tumor registry from 2007 to 2017. The inclusion criteria included those diagnosed with stage I to IV colon cancer at 18 years of age and above. Exclusion criteria included a diagnosis of both RCC and LCC and patients under age 18. The median of overall survival and time to recurrence between LCC and RCC were compared using Wilcoxon Rank Sum Test with two-sided significance level at 0.05. Results: Time to overall survival and time to recurrence was shown to have no significant difference between RCC and LCC (p = 0.3398 and 0.9467, respectively). Cox proportional hazards model adjusted for age and sex also support the claim (p = 0.1725 and 0.0633). There was a statistically significant difference in age between the two groups with the older mean age seen in RCC (68 versus 62). The distribution of recurrence was statistically significant with a higher recurrence in RCC (p = 0.0105). Conclusions: Unlike CALGB/SWOG 80405, our analysis included the transverse colon as part of RCC and examined stage I to IV colon cancer to ultimately conclude that there was no significant difference in overall survival or time to recurrence. Our study suggests that tumor location is not an independent prognostic factor on survival for all stages of colon cancer. However, a higher suspicion for recurrence may be needed for those diagnosed with RCC. Future investigations involving molecular subtypes and mutations are needed to further clarify prognosis and tumor sidedness.
Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor
Authors: Paula Rodriguez Otero, Maria-Victoria Mateos, Joaquin Martinez Lopez, Miguel-Teodoro Hernández, Enrique M. Ocio, Laura Rosiñol, Rafael Martínez, Ana Isabel Teruel, Norma C. Gutierrez, Joan Bargay, Enrique Bengoechea, Yolanda Gonzalez-Montes, Jaime Perez De Oteyza, Mercedes Gironella, Cristina Encinas, Jesús Martín, Carmen Cabrera, Luis Palomera, Felipe De Arriba, Maria Teresa Cedena Romero, Noemi Puig, Albert Oriol, Bruno Paiva, Joan Bladé, Juan Jose Lahuerta, Jesus F San-Miguel
Journal: Blood (2018)
Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms
Authors: Yasutaka Ueda, Hiroyuki Takamori, Jun-Ho Jang, Chezi Ganzel, Saskia Langemeijer, Makiko Osato, Petra Muus, Jong-Wook Lee, Jun-Ichi Nishimura, Yuzuru Kanakura
Journal: Blood (2018)
Cysteinyl Leukotriene Receptor 2 Drives IL-33-Mediated Aspirin Sensitivity Through A Platelet Dependent Mechanism
Authors: Tao Liu, Nora A. Barrett, Yoshihide Kanaoka, Tanya M. Laidlaw, Eri Yoshimoto, Denise Garofalo, Chunli Feng, Joshua A. Boyce
Journal: Journal of Allergy and Clinical Immunology (2019)
Oncologic outcomes after laparoscopic and open distal gastrectomy for advanced gastric cancer: A propensity score matching analysis.
Authors: Yoona Chung, Sung Il Choi, Kyungpyo Hong, Sanghyun Kim
Journal: Journal of Clinical Oncology (2019)

135 Background: The aim of this study is to investigate the oncologic outcomes as well as short-term outcomes of laparoscopic distal gastrectomy compared with open distal gastrectomy for advanced gastric cancer using propensity-score matching analysis. Methods: A total of 384 patients underwent distal gastrectomy for advanced gastric cancer from July 2006 to November 2016. Data on short- and long-term outcomes were collected prospectively and reviewed. Propensity-score matching was applied at a ratio of 1:1 comparing the laparoscopic distal gastrectomy (LDG) group and open distal gastrectomy (ODG) groups. Results: The LDG group showed longer operative time than the ODG group. However, resumption of diet and length of hospital stay were shorter in the LDG group than in the ODG group (4.7 vs. 5.6 days, p= 0.049 and 9.6 vs. 11.5 days, p= 0.035, respectively).The extent of lymph node dissection in the LDG group was more limited than in the ODG group ( p= 0.002), although there was no difference in the number of retrieved lymph nodes between the two groups. The 3-year overall survival rates were 98% and 86.9% ( p= 0.018), whereas the 3-year recurrence-free survival were 86.3% and 75.3%, p= 0.259) in the LDG and the ODG groups. Conclusions: Laparoscopic distal gastrectomy is safe and feasible for advanced gastric cancer in terms of earlier recovery after surgery and long-term oncologic outcomes.
Author Correction: Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza
Authors: Jake Dunning, Simon Blankley, Long T. Hoang, Mike Cox, Christine M. Graham, Philip L. James, Chloe I. Bloom, Damien Chaussabel, Jacques Banchereau, Stephen J. Brett, Miriam F. Moffatt, Anne O’Garra, Peter J. M. Openshaw
Journal: Nature Immunology (2019)
Anaphylaxis: comparison of clinical characteristics and management between children less than 2 years of age and older children
Authors: John D. Molloy, Sofianne Gabrielli, Ann Elaine Clarke, Judy Morris, Jocelyn Gravel, Paul Enarson, Edmond S. Chan, Andrew O'Keefe, Robert Porter, Rodrick Lim, Moshe Ben-Shoshan
Journal: Journal of Allergy and Clinical Immunology (2019)
Assisted dying: the debate continues
Authors: Fiona Godlee
Journal: BMJ (2019)

What would it mean if the UK’s doctors moved to adopt a neutral stance on the question of assisted dying? The BMJ has advocated such a move for some years, arguing that the question of whether assisted dying should be legalised is a matter for society rather than the medical profession (doi:10.1136/bmj.e4075). Last week we heard from Sandy Buchman, president elect of the Canadian Medical Association, about his own change of heart on assisted dying (doi:10.1136/bmj.l412). We also heard from Jeff Blackmer how, in his view, the CMA’s decision to adopt a neutral stance has allowed it to …
Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients
Authors: Gang Lv, Guo-qiang Wang, Zhen-xi Xia, Hai-xia Wang, Nan Liu, Wei Wei, Yong-hua Huang, Wei-wei Zhang
Journal: Military Medical Research (2019)

To study the influence of blood lipid levels on hemorrhagic transformation (HT) and prognosis after acute cerebral infarction (ACI).Patients with ACI within 72 h of symptoms onset between January 1st, 2015, and December 31st, 2016, were retrospectively analyzed. Patients were divided into group A (without HT) and group B (HT). The outcomes were assessed after 3 months of disease onset using the modified Rankin Scale (mRS). An mRS score of 0-2 points indicated excellent prognosis, and an mRS score of 3-6 points indicated poor prognosis.A total of 732 patients conformed to the inclusion criteria, including 628 in group A and 104 in group B. The incidence of HT was 14.2%, and the median onset time was 2 d (interquartile range, 1-7 d). The percentages of patients with large infarct size and cortex involvement in group B were 80.8 and 79.8%, respectively, which were both significantly higher than those in group A (28.7 and 33.4%, respectively). The incidence rate of atrial fibrillation (AF) in group B was significantly higher than that in group A (39.4% vs. 13.9%, P < 0.001). The adjusted multivariate analysis results showed that large infarct size, cortex involvement and AF were independent risk factors of HT, while total cholesterol (TC) was a protective factor of HT (OR = 0.359, 95% CI 0.136-0.944, P = 0.038). With every 1 mmol/L reduction in normal TC levels, the risk of HT increased by 64.1%. The mortality and morbidity at 3 months in group B (21.2 and 76.7%, respectively) were both significantly higher than those in group A (8.0 and 42.8%, respectively). The adjusted multivariate analysis results showed that large infarct size (OR = 12.178, 95% CI 5.390-27.516, P < 0.001) was an independent risk factor of long-term unfavorable outcomes, whereas low-density lipoprotein cholesterol (LDL-C) was a protective factor (OR = 0.538, 95% CI 0.300-0.964, P = 0.037). With every 1 mmol/L reduction in normal LDL-C levels, the risk of an unfavorable outcome increased by 46.2%. Major therapies, including intravenous recombinant human tissue plasminogen activator (rTPA), intensive lipid-lowering statins and anti-platelets, were not significantly related to either HT or long-term, post-ACI poor prognosis.For patients with large infarct sizes, especially those with cortex involvement, AF, or lower levels of TC, the risk of HT might increase after ACI. The risk of a long-term unfavorable outcome in these patients might increase with a reduction in LDL-C.
Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma
Authors: Leo Rasche, Manoj Kumar, Grant Gershner, James E McDonald, Samrat Roy Choudhury, Rudy L. Van Hemert, Joshua Epstein, Sharmilan Thanendrarajan, Carolina D. Schinke, Frits van Rhee, Maurizio Zangari, Bart Barlogie, Faith E. Davies, Gareth Morgan, Niels Weinhold
Journal: Blood (2018)
Readmission and reoperation rates following negative diagnostic laparoscopy for clinically suspected appendicitis: The “normal” appendix should not be removed – A retrospective cohort study
Authors: Amira Khattar Sørensen, Anders Bang-Nielsen, Katarina Levic-Souzani, Hans Christian Pommergaard, Anders Beck Jørgensen, Mai-Britt Tolstrup, Bo Rud, Bojan Kovacevic, Orhan Bulut
Journal: International Journal of Surgery (2019)
Mouse hepatitis virus type 3 infection provokes a decrease in the number of sinusoidal endothelial cell fenestrae both in vivo and in vitro
Authors: A STEFFAN
Journal: Hepatology (1995)

Fenestrations of hepatic endothelial cells play an active role as a sieving barrier allowing extensive exchange between the blood and liver parenchyma. Alteration of these structures may be induced in the course of various pathological events and provoke important perturbations of liver function. We demonstrate here that sinusoidal endothelial cells are permissive for mouse hepatitis virus 3 (MHV3) in vivo and in vitro and that this infection leads to a striking decrease in the number of fenestrae. The disappearance of these structures observed under scanning electron microscopy or in cryofracture preparations in vivo and in vitro cannot be reversed by the action of cytochalasin B on the microfilament network. The decrease in the porosity seems to be related directly to the productive infection of the endothelial cells, because it was not observed in A/J mice resistant to the virus and in susceptible BALB/c mice immunized with a thermosensitive mutant in which no viral replication occurs. In conclusion, a viral infection of liver endothelial cells may cause extensive loss of the fenestrations and thus lead to important functional pertubations.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Authors: Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sergio J. Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Yen-Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles
Journal: New England Journal of Medicine (2019)

The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.
Extracting Diagnostic Data from Unstructured Bone Marrow Biopsy Reports of Myeloid Neoplasms Utilizing a Customized Natural Language Processing (NLP) Algorithm
Authors: Isaac Kunz, Ananth Peddinti, Tina Nguyen, Morgan Ward, Alexandra Asay, Michael W. Deininger, Srinivas K. Tantravahi, Samir Courdy
Journal: Blood (2018)